New York: CureVac BV soared 249% in its trading debut after raising $213 million in a U.S. initial public offering that boosted its profile in the race for a coronavirus vaccine.
It was the best first-day performance by a wide margin among about 200 new listings on U.S. exchanges this year, according to data compiled by Bloomberg.
“It is definitely a race,” CureVac Chief Executive Officer Franz-Werner Haas said in a Bloomberg TV interview. “It is a race not that much against the competition of other vaccine producers out there but a race against the virus. It is a race against time.”
The company’s shares closed at $55.90 in New York trading Friday, giving the company a market value of $9.86 billion. CureVac sold 13.33 million shares Thursday for $16 each after marketing them for $14 to $16.
CureVac, based in Tubingen, Germany, is also raising 100 million euros ($118 million) in a private placement concurrent with the IPO, according to CureVac’s filings with the U.S. Securities and Exchange Commission.
The German government agreed in June to acquire 23% of the company for 300 million euros via development bank Kreditanstalt fuer Wiederaufbau, known as KfW.
We are deeply grateful to our readers & viewers for their time, trust and subscriptions.
Quality journalism is expensive and needs readers to pay for it. Your support will define our work and ThePrint’s future.
The offering was led by Bank of America Corp., Jefferies Financial Group Inc. and Credit Suisse Group AG. Shares of the company, which is being incorporated in the Netherlands and renamed CureVac NV in conjunction with the IPO, are trading on the Nasdaq Global Market under the symbol CVAC.
CureVac, founded in 2000, said in June that it received regulatory approval to begin Phase 1 clinical trials of its Covid-19 vaccine candidate. It said in its filing that it expects the results of those trials in the fourth quarter.
As the coronavirus pandemic took hold, CureVac became the prize in a transatlantic competition to secure access to a potential vaccine after reports that the U.S. was angling to buy the company or its technology. In March, CureVac denied speculation that the U.S. government tried to buy the business or its technology.
CureVac’s research is focused on messenger RNA, in which the vaccine teaches the body’s cells to identify and attack the virus. Some other companies trying to develop coronavirus vaccines, including Moderna Inc., based in Cambridge, Massachusetts, and German rival BioNTech SE, are already public.
Moderna shares rose 2% on Friday, while BioNTech’s American depositary receipts fell 3.3%. The now second-best first-day performance for U.S. IPO is BigCommerce Holdings Inc., which closed up 201% in its debut.- Bloomberg
News media is in a crisis & only you can fix it
You are reading this because you value good, intelligent and objective journalism. We thank you for your time and your trust.
You also know that the news media is facing an unprecedented crisis. It is likely that you are also hearing of the brutal layoffs and pay-cuts hitting the industry. There are many reasons why the media’s economics is broken. But a big one is that good people are not yet paying enough for good journalism.
We have a newsroom filled with talented young reporters. We also have the country’s most robust editing and fact-checking team, finest news photographers and video professionals. We are building India’s most ambitious and energetic news platform. And we aren’t even three yet.
At ThePrint, we invest in quality journalists. We pay them fairly and on time even in this difficult period. As you may have noticed, we do not flinch from spending whatever it takes to make sure our reporters reach where the story is. Our stellar coronavirus coverage is a good example. You can check some of it here.
This comes with a sizable cost. For us to continue bringing quality journalism, we need readers like you to pay for it. Because the advertising market is broken too.
If you think we deserve your support, do join us in this endeavour to strengthen fair, free, courageous, and questioning journalism, please click on the link below. Your support will define our journalism, and ThePrint’s future. It will take just a few seconds of your time.